MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/jog.70289

Медицинская библиотека · The journal of obstetrics and gynaecology research · 2026

Clinicopathological Status and Prognostic Factors of Recurrent Epithelial Ovarian Cancer in Japan: Retrospective Survey of JSOG Committee on Gynecologic Oncology.

Watanabe Yoh, Baba Tsukasa, Soeda Shu, Tokunaga Hideki, Yamagami Wataru, Nomura Hiroyuki, Kobayashi Yoichi, Kawana Kei, Yoshino Kiyoshi, Yokoyama Yoshihito, Nishi Hirotaka, Kobayashi Hiroaki, Matsuzawa Yukiko, Oyamada Shunsuke, Takahashi Satoru, Nagase Satoru

СтатьяПеревод в очереди

Аннотация

AIM: Despite advancements in maintenance therapies, recurrent epithelial ovarian cancer remains a clinical challenge with varying outcomes. This study aimed to evaluate the clinicopathological status and prognostic factors of patients with recurrent epithelial ovarian cancer.

METHODS

We conducted a retrospective survey through the Committee on Gynecologic Oncology of the Japan Society of Gynecology and Obstetrics across 16 institutions.

RESULTS

Histological subtypes included high-grade serous (HGS; n = 304), clear-cell (CC; n = 83), endometrioid (EM; n = 35), mucinous (n = 12), and low-grade serous (n = 9) carcinomas. At recurrence, the median age was 61 years, 74.0% of patients had a platinum-free interval (PFI) ≥ 6 months, and 78.8% maintained a performance status (PS) of 0. Genetic testing identified 42 BRCA1/2 mutations and 52 cases of homologous recombination deficiency positivity. Recurrence occurred primarily in the peritoneum, lymph nodes, and liver. For PFI ≥ 6 months, paclitaxel/carboplatin ± bevacizumab was the primary treatment; for PFI < 6 months, pegylated liposomal doxorubicin ± bevacizumab predominated. The overall response rate was 69.9% for PFI ≥ 6 months versus 17.7% for PFI < 6 months. Median overall survival was 27.9 months. Multivariate analysis confirmed histological subtype (CC/EM vs. HGS), PS, CA125 (≥ 100 U/mL), and PFI as significant independent prognostic factors, while first-line molecularly targeted therapy use showed no significant impact.

CONCLUSION

PFI, histological subtype, PS, and CA125 levels are important prognostic factors for the use of molecular-targeted agents for recurrent epithelial ovarian cancer. Patients with CC and EM subtypes experience worse outcomes than those with HGS, highlighting the need for subtype-specific management in recurrent ovarian cancer.

Для цитирования: Watanabe Yoh, Baba Tsukasa, Soeda Shu, Tokunaga Hideki, Yamagami Wataru, Nomura Hiroyuki, Kobayashi Yoichi, Kawana Kei, Yoshino Kiyoshi, Yokoyama Yoshihito, Nishi Hirotaka, Kobayashi Hiroaki, Matsuzawa Yukiko, Oyamada Shunsuke, Takahashi Satoru, Nagase Satoru. Clinicopathological Status and Prognostic Factors of Recurrent Epithelial Ovarian Cancer in Japan: Retrospective Survey of JSOG Committee on Gynecologic Oncology.. The journal of obstetrics and gynaecology research. 2026. DOI: 10.1111/jog.70289.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.